Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
2.
Blood ; 144(5): 510-524, 2024 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-38684038

RESUMO

ABSTRACT: The T-box transcription factor T-bet is known as a master regulator of the T-cell response but its role in malignant B cells has not been sufficiently explored. Here, we conducted single-cell resolved multi-omics analyses of malignant B cells from patients with chronic lymphocytic leukemia (CLL) and studied a CLL mouse model with a genetic knockout of Tbx21. We found that T-bet acts as a tumor suppressor in malignant B cells by decreasing their proliferation rate. NF-κB activity, induced by inflammatory signals provided by the microenvironment, triggered T-bet expression, which affected promoter-proximal and distal chromatin coaccessibility and controlled a specific gene signature by mainly suppressing transcription. Gene set enrichment analysis identified a positive regulation of interferon signaling and negative control of proliferation by T-bet. In line, we showed that T-bet represses cell cycling and is associated with longer overall survival of patients with CLL. Our study uncovered a novel tumor suppressive role of T-bet in malignant B cells via its regulation of inflammatory processes and cell cycling, which has implications for the stratification and therapy of patients with CLL. Linking T-bet activity to inflammation explains the good prognostic role of genetic alterations in the inflammatory signaling pathways in CLL.


Assuntos
Proliferação de Células , Leucemia Linfocítica Crônica de Células B , Proteínas com Domínio T , Leucemia Linfocítica Crônica de Células B/patologia , Leucemia Linfocítica Crônica de Células B/genética , Leucemia Linfocítica Crônica de Células B/imunologia , Leucemia Linfocítica Crônica de Células B/metabolismo , Proteínas com Domínio T/genética , Proteínas com Domínio T/metabolismo , Animais , Humanos , Camundongos , Linfócitos B/patologia , Linfócitos B/metabolismo , Linfócitos B/imunologia , Camundongos Knockout , Regulação Leucêmica da Expressão Gênica , NF-kappa B/metabolismo
4.
Trends Plant Sci ; 29(4): 385-387, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38135603

RESUMO

Non-expressor of pathogenesis-related 1 (NPR1) acts as master regulator of plant immunity by promoting salicylic acid (SA) signalling. Some bacterial and fungal pathogens target NPR1 to inhibit SA-mediated immunity. Recently, Zhang et al. and Liu et al. demonstrated that a diverse spectrum of plant-infecting viruses have evolved distinct counter-defence strategies to weaken NPR1-mediated antiviral defence.


Assuntos
Proteínas de Arabidopsis , Arabidopsis , Vírus de Plantas , Proteínas de Arabidopsis/genética , Proteínas de Arabidopsis/metabolismo , Arabidopsis/metabolismo , Ácido Salicílico , Imunidade Vegetal , Bactérias/metabolismo , Regulação da Expressão Gênica de Plantas
5.
Leukemia ; 38(7): 1511-1521, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38486128

RESUMO

Loss-of-function mutations in NFKBIE, which encodes for the NF-κB inhibitor IκBε, are frequent in chronic lymphocytic leukemia (CLL) and certain other B-cell malignancies and have been associated with accelerated disease progression and inferior responses to chemotherapy. Using in vitro and in vivo murine models and primary patient samples, we now show that NFKBIE-mutated CLL cells are selected by microenvironmental signals that activate the NF-κB pathway and induce alterations within the tumor microenvironment that can allow for immune escape, including expansion of CD8+ T-cells with an exhausted phenotype and increased PD-L1 expression on the malignant B-cells. Consistent with the latter observations, we find increased expression of exhaustion markers on T-cells from patients with NFKBIE-mutated CLL. In addition, we show that NFKBIE-mutated murine CLL cells display selective resistance to ibrutinib and report inferior outcomes to ibrutinib treatment in NFKBIE-mutated CLL patients. These findings suggest that NFKBIE mutations can contribute to CLL progression through multiple mechanisms, including a bidirectional crosstalk with the microenvironment and reduced sensitivity to BTK inhibitor treatment.


Assuntos
Adenina , Leucemia Linfocítica Crônica de Células B , Mutação , Piperidinas , Evasão Tumoral , Microambiente Tumoral , Animais , Humanos , Camundongos , Adenina/análogos & derivados , Adenina/farmacologia , Linfócitos T CD8-Positivos/imunologia , Leucemia Linfocítica Crônica de Células B/genética , Leucemia Linfocítica Crônica de Células B/patologia , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Leucemia Linfocítica Crônica de Células B/imunologia , NF-kappa B/metabolismo , Piperidinas/farmacologia , Piperidinas/uso terapêutico , Pirazóis/farmacologia , Pirazóis/uso terapêutico , Pirimidinas/farmacologia , Pirimidinas/uso terapêutico , Evasão Tumoral/genética , Microambiente Tumoral/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA